Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Collaborative Neuroscience Network Inc

Neither a doctor nor a teaching hospital

Research payments

$2,655,347

233 payments

Through program year 2025, Collaborative Neuroscience Network Inc is reported as receiving $2,655,347 in research payments, across 233 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $465 1
2024 Research $1,155 1
2023 Research $1,009 2
2022 Research $12,625 10
2021 Research $109,016 32
2020 Research $415,793 90
2019 Research $2,115,283 97

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $2,199,373 148 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $144,459 6 payments
  3. Roche TCRC, Inc. $117,382 12 payments
  4. Eli Lilly and Company $93,176 28 payments
  5. Sage Therapeutics, Inc. $80,146 32 payments
  6. Amgen Inc. $13,812 5 payments
  7. EMD Serono, Inc. $6,999 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $2,085,674 108 payments
  2. The Effect of 24Week Treatment With Basmisanil on Cognitive Impairment Associated With Schizophrenia $117,382 12 payments
  3. Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder $66,522 1 payment
  4. Effect of Ly3154207 on Cognition in Mild to Moderate Parkinsons Disease Dementia PDD - the Presence Study $62,170 5 payments
  5. Tv46000-Ba-10148 $56,403 14 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia $47,574 18 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $36,555 2 payments
  8. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $31,600 13 payments
  9. 217-Mdd-302 $28,626 6 payments
  10. Phase 2, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Trial of Brexpiprazole 1 - 3 Mgday As Monotherapy Or As Combination Therapy in the Treatment of Adults With Post-Traumatic Stress Disorder $19,202 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record